阿尔茨海默病血浆生物标志物的研究进展
Research Progress on Plasma Biomarkers of Alzheimer’s Disease
DOI: 10.12677/acm.2025.15102850, PDF,    科研立项经费支持
作者: 陈泠羽, 王建行, 陈肖杰, 赵泳莉, 李施雨：牡丹江医科大学研究生院，黑龙江 牡丹江；赵维纳*：牡丹江市北药资源开发与应用协同创新中心，黑龙江 牡丹江
关键词: 阿尔茨海默病；临床前期；血清学标记物；早期识别；Alzheimer’s Disease； Preclinical； Serological Markers； Early Identification
摘要: 阿尔茨海默病(Alzheimer’s disease, AD)是世界上导致痴呆的最常见疾病。早期诊断阿尔茨海默病通过使用生物标志物可以促进早期治疗干预措施的建立和监测，这些干预措施有可能显著改变患者的疾病进程，识别神经系统疾病液体生物标志物的早期主要集中在脑脊液(CSF)上。而它们的广泛使用，例如筛查测试，受到腰椎穿刺手术侵入性的巨大限制，和其高昂的成本。来自大脑和脑脊液的蛋白质最终进入血液，然后在血液中被稀释。在过去的几年里，各种研究表明，一些生物标记物可以在血液中检测到，确定更容易获得和更便宜的生物标志物。本篇总结了AD主要的血清生物标志物研究进展进行综述。
Abstract: Alzheimer’s disease (AD) is the most common disease that causes dementia in the world. Early diagnosis of Alzheimer’s disease can facilitate the establishment and monitoring of early treatment interventions through the use of biomarkers, which have the potential to significantly alter the disease course in patients, and the early identification of liquid biomarkers of neurological diseases is mainly focused on cerebrospinal fluid (CSF). And their widespread use, such as screening tests, is greatly limited by the invasiveness of lumbar puncture surgery, and its high cost. Proteins from the brain and cerebrospinal fluid end up in the bloodstream, where they are then diluted. Over the past few years, various studies have shown that some biomarkers can be detected in the blood, identifying more accessible and less expensive biomarkers. This article summarizes the research progress of the main serum biomarkers of AD.
文章引用：陈泠羽, 王建行, 陈肖杰, 赵泳莉, 李施雨, 赵维纳. 阿尔茨海默病血浆生物标志物的研究进展[J]. 临床医学进展, 2025, 15(10): 1020-1026. https://doi.org/10.12677/acm.2025.15102850

参考文献

[1] Jia, J., Wei, C., Chen, S., Li, F., Tang, Y., Qin, W., et al. (2018) The Cost of Alzheimer’s Disease in China and Re‐estimation of Costs Worldwide. Alzheimer’s & Dementia, 14, 483-491. [Google Scholar] [CrossRef] [PubMed]
[2] Karlawish, J. and Grill, J.D. (2024) Alzheimer’s Disease Biomarkers and the Tyranny of Treatment. eBioMedicine, 108, Article 105291. [Google Scholar] [CrossRef] [PubMed]
[3] Ma, C., Hong, F. and Yang, S. (2022) Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 27, Article 1210. [Google Scholar] [CrossRef] [PubMed]
[4] Huang, Y. and Liu, R. (2020) The Toxicity and Polymorphism of β-Amyloid Oligomers. International Journal of Molecular Sciences, 21, Article 4477. [Google Scholar] [CrossRef] [PubMed]
[5] Tiwari, S., Atluri, V., Kaushik, A., Yndart, A. and Nair, M. (2019) Alzheimer’s Disease: Pathogenesis, Diagnostics, and Therapeutics. International Journal of Nanomedicine, 14, 5541-5554. [Google Scholar] [CrossRef] [PubMed]
[6] Li, C. and Götz, J. (2017) Tau-Based Therapies in Neurodegeneration: Opportunities and Challenges. Nature Reviews Drug Discovery, 16, 863-883. [Google Scholar] [CrossRef] [PubMed]
[7] Ovod, V., Ramsey, K.N., Mawuenyega, K.G., Bollinger, J.G., Hicks, T., Schneider, T., et al. (2017) Amyloid Β Concentrations and Stable Isotope Labeling Kinetics of Human Plasma Specific to Central Nervous System Amyloidosis. Alzheimer’s & Dementia, 13, 841-849. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, D., Zhang, W., Ming, C., Gao, X., Yuan, H., Lin, X., et al. (2024) P-Tau217 Correlates with Neurodegeneration in Alzheimer’s Disease, and Targeting P-Tau217 with Immunotherapy Ameliorates Murine Tauopathy. Neuron, 112, 1676-1693.E12. [Google Scholar] [CrossRef] [PubMed]
[9] Doroszkiewicz, J., Groblewska, M. and Mroczko, B. (2022) Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases. International Journal of Molecular Sciences, 23, Article 4610. [Google Scholar] [CrossRef] [PubMed]
[10] Gonzalez-Ortiz, F., Kac, P.R., Brum, W.S., Zetterberg, H., Blennow, K. and Karikari, T.K. (2023) Plasma Phospho-Tau in Alzheimer’s Disease: Towards Diagnostic and Therapeutic Trial Applications. Molecular Neurodegeneration, 18, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[11] Milà-Alomà, M., Ashton, N.J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., et al. (2022) Plasma P-Tau231 and P-Tau217 as State Markers of Amyloid-Β Pathology in Preclinical Alzheimer’s Disease. Nature Medicine, 28, 1797-1801. [Google Scholar] [CrossRef] [PubMed]
[12] Li, L., Che, P., Liu, D., Wang, Y., Li, J., He, D., et al. (2025) Diagnostic and Discriminative Accuracy of Plasma Phosphorylated Tau 217 for Symptomatic Alzheimerʼs Disease in a Chinese Cohort. The Journal of Prevention of Alzheimer’s Disease, 12, Article 100092. [Google Scholar] [CrossRef] [PubMed]
[13] Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L. and Zetterberg, H. (2019) Neurofilament Light Chain as a Biomarker in Neurological Disorders. Journal of Neurology, Neurosurgery & Psychiatry, 90, 870-881. [Google Scholar] [CrossRef] [PubMed]
[14] Palermo, G., Mazzucchi, S., Della Vecchia, A., Siciliano, G., Bonuccelli, U., Azuar, C., et al. (2020) Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. Molecular Neurobiology, 57, 4667-4691. [Google Scholar] [CrossRef] [PubMed]
[15] Gallingani, C., Carbone, C., Tondelli, M. and Zamboni, G. (2024) Neurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates. Brain Sciences, 14, Article 272. [Google Scholar] [CrossRef] [PubMed]
[16] Nicsanu, R., Cervellati, C., Benussi, L., Squitti, R., Zanardini, R., Rosta, V., et al. (2022) Increased Serum Beta-Secretase 1 Activity Is an Early Marker of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 87, 433-441. [Google Scholar] [CrossRef] [PubMed]
[17] Saraceno, C., Cervellati, C., Trentini, A., Crescenti, D., Longobardi, A., Geviti, A., et al. (2024) Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study. International Journal of Molecular Sciences, 25, Article 8354. [Google Scholar] [CrossRef] [PubMed]
[18] Pang, K., Jiang, R., Zhang, W., Yang, Z., Li, L., Shimozawa, M., et al. (2022) An App Knock-In Rat Model for Alzheimer’s Disease Exhibiting Aβ and Tau Pathologies, Neuronal Death and Cognitive Impairments. Cell Research, 32, 157-175. [Google Scholar] [CrossRef] [PubMed]
[19] Triaca, V., Ruberti, F. and Canu, N. (2021) NGF and the Amyloid Precursor Protein in Alzheimer’s Disease: From Molecular Players to Neuronal Circuits. In: Calzà, L., Aloe, L. and Giardino, L., Eds., Advances in Experimental Medicine and Biology, Springer International Publishing, 145-165. [Google Scholar] [CrossRef] [PubMed]
[20] Maurya, R., Bhattacharjee, G., Khambhati, K., et al. (2023) Amyloid Precursor Protein in Alzheimer’s Disease. Progress in Molecular Biology and Translational Science, 196, 261-270.
[21] Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., et al. (2024) APOE4 Homozygosity Represents a Distinct Genetic Form of Alzheimer’s Disease. Nature Medicine, 30, 1284-1291. [Google Scholar] [CrossRef] [PubMed]
[22] Ferrari-Souza, J.P., Bellaver, B., Ferreira, P.C.L., Benedet, A.L., Povala, G., Lussier, F.Z., et al. (2023) APOEε4 Potentiates Amyloid Β Effects on Longitudinal Tau Pathology. Nature Aging, 3, 1210-1218. [Google Scholar] [CrossRef] [PubMed]
[23] Scarabino, D., Broggio, E., Gambina, G., Maida, C., Gaudio, M.R. and Corbo, R.M. (2016) Apolipoprotein E Genotypes and Plasma Levels in Mild Cognitive Impairment Conversion to Alzheimer’s Disease: A Follow‐Up Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 171, 1131-1138. [Google Scholar] [CrossRef] [PubMed]
[24] Abdullah, L., Evans, J.E., Emmerich, T., Crynen, G., Shackleton, B., Keegan, A.P., et al. (2017) APOE ε4 Specific Imbalance of Arachidonic Acid and Docosahexaenoic Acid in Serum Phospholipids Identifies Individuals with Preclinical Mild Cognitive Impairment/Alzheimer’s Disease. Aging, 9, 964-985. [Google Scholar] [CrossRef] [PubMed]
[25] Prins, S., de Kam, M.L., Teunissen, C.E., et al. (2022) Inflammatory Plasma Biomarkers in Subjects with Preclinical Alzheimer’s Disease. Alzheimer’s Research & Therapy, 14, Article 106.
[26] Nie, C., Sun, Y., Zhen, H., Guo, M., Ye, J., Liu, Z., et al. (2020) Differential Expression of Plasma Exo-Mirna in Neurodegenerative Diseases by Next-Generation Sequencing. Frontiers in Neuroscience, 14, Article 438. [Google Scholar] [CrossRef] [PubMed]
[27] Lugli, G., Cohen, A.M., Bennett, D.A., Shah, R.C., Fields, C.J., Hernandez, A.G., et al. (2015) Plasma Exosomal Mirnas in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLOS ONE, 10, e0139233. [Google Scholar] [CrossRef] [PubMed]
[28] Li, W. and Zheng, Y. (2023) MicroRNAs in Extracellular Vesicles of Alzheimer’s Disease. Cells, 12, Article 1378. [Google Scholar] [CrossRef] [PubMed]
[29] Salta, E. and De Strooper, B. (2017) MicroRNA‐132: A Key Noncoding RNA Operating in the Cellular Phase of Alzheimer’s Disease. The FASEB Journal, 31, 424-433. [Google Scholar] [CrossRef] [PubMed]
[30] Wu, H.Z.Y., Thalamuthu, A., Cheng, L., Fowler, C., Masters, C.L., Sachdev, P., et al. (2020) Differential Blood Mirna Expression in Brain Amyloid Imaging-Defined Alzheimer’s Disease and Controls. Alzheimer’s Research & Therapy, 12, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
[31] Varesi, A., Carrara, A., Pires, V.G., Floris, V., Pierella, E., Savioli, G., et al. (2022) Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview. Cells, 11, Article 1367. [Google Scholar] [CrossRef] [PubMed]
[32] Kim, M., Nevado-Holgado, A., Whiley, L., Snowden, S.G., Soininen, H., Kloszewska, I., et al. (2017) Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer’s Disease. Journal of Alzheimer’s Disease, 60, 809-817. [Google Scholar] [CrossRef] [PubMed]
[33] Akyol, S., Ugur, Z., Yilmaz, A., Ustun, I., Gorti, S.K.K., Oh, K., et al. (2021) Lipid Profiling of Alzheimer’s Disease Brain Highlights Enrichment in Glycerol(Phospho)Lipid, and Sphingolipid Metabolism. Cells, 10, Article 2591. [Google Scholar] [CrossRef] [PubMed]
[34] Lista, S., Imbimbo, B.P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., et al. (2024) Tracking Neuroinflammatory Biomarkers in Alzheimer’s Disease: A Strategy for Individualized Therapeutic Approaches? Journal of Neuroinflammation, 21, Article No. 187. [Google Scholar] [CrossRef] [PubMed]
[35] Delaby, C., Hirtz, C. and Lehmann, S. (2023) Overview of the Blood Biomarkers in Alzheimer’s Disease: Promises and Challenges. Revue Neurologique, 179, 161-172. [Google Scholar] [CrossRef] [PubMed]

为你推荐